检索结果-南通市图书馆

Preclinical therapy of benign prostatic hyperplasia with neuropeptide hormone antagonists

World Journal of Clinical Urology 2014年第3期3卷 184-194页

作者： petra popovics Andrew V Schally Norman L Block Ferenc G Rick Division of Cardiovascular Diseases Department of Medicine Miller School of Medicine University of MiamiMiami FL 33136 United States Department of Medicine Ⅲ Medical Faculty Carl Gustav CarusD-01307 TU Dresden Germany Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education Miami FL 33125 United States Divisions of Hematology/Oncology and Endocrinology Department of Medicine Miller School of Medicine University of MiamiMiami FL 33136 United States Department of Urology Florida International University Herbert Wertheim College of MedicineMiami FL 33199 United States

Benign prostatic hyperplasia(BPH)is a pathologic condition of the prostate described as a substantial increase in its number of epithelial and stromal *** may significantly reduce the quality of life due to the initiation of bladder outlet obstruction and lower urinary tract *** medical therapies mostly consist of inhibitors of 5α-reductase orα1-adrenergic blockers;their efficacy is often *** analogs of neuropeptide hormones are novel candidates for the management of *** first,antagonists of luteinizing hormone-releasing hormone(LHRH)have been introduced to the therapy aimed to reduce serum testosterone ***,they have also been found to produce an inhibitory activity on local LHRH receptors in the prostate as well as impotence and other related side *** then,several preclinical and clinical studies reported the favorable effects of LHRH antagonists in *** contrast,antagonists of growth hormone-releasing hormone(GHRH)and gastrin-releasing peptide(GRP)have been tested only in preclinical settings and produce significant reduction in prostate size in experimental models of *** act at least in part,by blocking the action of respective ligands produced locally on prostates through their respective receptors in the prostate,and by inhibition of autocrine insulin-like growth factors-Ⅰ/Ⅱand epidermal growth factor *** and LHRH antagonists were also tested in combination resulting in a cumulative effect that was greater than that of each *** article will review the numerous studies that demonstrate the beneficial effects of antagonistic analogs of LHRH,GHRH and GRP in BPH,as well as suggesting a potential role for somatostatin analogs in experimental therapies.

关键词： Benign prostatic hyperplasia Luteinizing hormone-releasing hormone Growth hormone-releasing hormone Gastrin-releasing peptide Somatostatin Targeted therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：